Value of Fecal Calprotectin in Activity Evaluation of Ulcerative Colitis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

KUAI Guohu ,  LI Chunyu

Department of Colorectal Surgery， The Forth Affiliated Hospital， China Medical University， Shenyang 110032， Liaoning Province， China;

Corresponding author：

LI Chunyu, Email: lcy133000@163.com

Keywords：

Ulcerative colitis; Fecal calprotectin; C-reactive protein; Erythrocyte sedimentation rate; Activity

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To explore the value of fecal calprotectin （FCP） in the activity evaluation for ulcerative colitis （UC）.
Methods 　Sixty three patients with UC （UC group） and 30 patients with gastrointestinal symptoms but without abnormal results of colonoscopy （control group）， who were treated in The Forth Affiliated Hospital of China Medical University between Sep. 2007 to Dec. 2009 were enrolled to examine the FCP， C-creative protein （CRP）， and erythrocyte sedimentation rate （ESR）. Then comparison between UC group and control group was performed.
Results　Levels of FCP and CRP in active gradeⅠ，Ⅱ， and Ⅲ group were all significantly higher than those of control group and inactive UC group （P＜0.05）， with the increase of active grade of UC， the level of FCP gradually increased （P＜0.05）. The levels of CRP in active grade Ⅱ and Ⅲ group were all significantly higher than those of gradeⅠgroup （P＜0.05）， but didn’t differed between active grade Ⅱ and Ⅲ group （P＞0.05）. There were no significant difference among 5 groups on ESR （P＞0.05）. Levels of FCP （rs=0.807， P＜0.01）， CRP（rs=0.651， P＜0.01）， and ESR （rs=0.371， P＜0.05） in active grade group were significantly related to histological grade under colonoscopy.
Conclusion 　FCP examination is simple， inexpensive， repeatable， and noninvasive， and FCP can be used as an marker of activity evaluation in UC.

Citation： KUAI Guohu,LI Chunyu,.. Value of Fecal Calprotectin in Activity Evaluation of Ulcerative Colitis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2013, 20(6): 648-651. doi: Copy

1.	宋璐，夏冰. 溃疡性结肠炎发病机制及其诊断[J]. 中国实用内科杂志， 2010， 30(11)：1056-1058.
2.	Masoodi I， Tijjani BM， Wani H， et al. Biomarkers in the manag-ement of ulcerative colitis：a brief review[J]. Ger Med Sci， 2011，.
3.	中华医学会消化病学分会炎症性肠病协作组. 中国炎症性肠病诊断治疗规范的共识意见[J]. 中华内科杂志， 2008， 47(1)：73-79.
4.	Truelove SC， Witts LJ. Cortisone in ulcerative colitis；final reporton a therapeutic trial[J]. Br BMJ J， 1955， 2(4947)：1041-1048.
5.	Cosnes J， Gower-Rousseau C， Seksik P， et al. Epidemiology and natural history of inflammatory bowel diseases[J]. Gastroenterology， 2011， 140(6)：1785-1794.
6.	Fagerhol MK， Dale I， Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells[J]. Bull Eur Physiopathol Respir， 1980， 16 Suppl：273-282.
7.	Rugtveit J， Brandtzaeg P， Halstensen TS， et al. Increased macrophage subset in inflammatory bowel disease：apparent recruitment from peripheral blood monocytes[J]. Gut， 1994， 35(5)：669-674.
8.	Røseth AG， Aadland E， Jahnsen J， et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin， a novel granulocyte marker protein[J]. Digestion， 1997， 58(2)：176-180.
9.	：Doc03.
10.	Gisbert JP， McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease[J]. Dig Liver Dis， 2009， 41(1)：56-66.
11.	沈姞，李俊霞，王化虹，等. 粪便钙卫蛋白对溃疡性结肠炎的诊断及预测复发的价值[J]. 肠外与肠内营养， 2011， 18(5)：272-276.
12.	马列婷，王亚文，乔文. 粪便钙卫蛋白对溃疡性结肠炎诊断的临床价值[J]. 西安交通大学学报：医学版， 2008， 29(3)：321-323.
13.	Amati L， Passeri ME， Selicato F， et al. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease[J]. Immunopharmacol Immunotoxicol， 2006， 28(4)：665-681.
14.	Costa F， Mumolo MG， Ceccarelli L， et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease[J]. Gut， 2005， 54(3)：364-368.
15.	Tibble JA， Sigthorsson G， Bridger S， et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease[J]. Gastroenterology， 2000， 119(1)：15-22.
16.	张颖，王英德. 粪便钙卫蛋白、抗中性粒细胞胞浆抗体检测在溃疡性结肠炎诊断中的价值比较[J]. 中华临床医师杂志：电子版， 2012， 6(6)：1620-1622.
17.	Vermeire S， Van Assche G， Rutgeerts P. Laboratory markers in IBD：useful， magic， or unnecessary toys?[J]. Gut， 2006， 55(3)：426-431.
18.	Solem CA， Loftus EV Jr， Tremaine WJ， et al. Correlation ofC-reactive protein with clinical， endoscopic， histologic， and radio-graphic activity in inflammatory bowel disease[J]. Inflamm Bowel Dis， 2005， 11(8)：707-712.
19.	Manz M， Burri E， Rothen C， et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort：an observational study[J]. BMC Gastroenterol， 2012， 12：5.
20.	Erbayrak M， Turkay C， Eraslan E， et al. The role of fecal calprotectin in investigating inflammatory bowel diseases[J]. Clinics，.
21.	Schoepfer AM， Beglinger C， Straumann A， et al. Ulcerative colitis：correlation of the rachmilewitz endoscopic activity index with fecal calprotectin， clinical activity， C-reactive protein， and blood leukocytes[J]. Inflamm Bowel Dis， 2009， 15(12)：1851-1858.
22.	Lamb CA， Mohiuddin MK， Gicquel J， et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease[J]. Br J Surg， 2009， 96(6)：663-674.
23.	Fagerhol MK. Calprotectin， a faecal marker of organic gastrointestinal abnormality[J]. Lancet， 2000， 356(9244)：1783-1784.
24.	Mao R， Xiao YL， Gao X， et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases：a meta-analysis of pros-pective studies[J]. Inflamm Bowel Dis， 2012， 18(10)：1894-1899.
25.	Schoepfer AM， Beglinger C， Straumann A， et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the lichtiger index， C-reactive protein， platelets， hemoglobin， and blood leukocytes[J]. Inflamm Bowel Dis， 2013， 19(2)：332-341.
26.	欧阳钦. 溃疡性结肠炎的治疗[J]. 中国实用内科杂志， 2010， 30(4)：383-385.
27.	， 64(5)：421-425.

1. 宋璐，夏冰. 溃疡性结肠炎发病机制及其诊断[J]. 中国实用内科杂志， 2010， 30(11)：1056-1058.
2. Masoodi I， Tijjani BM， Wani H， et al. Biomarkers in the manag-ement of ulcerative colitis：a brief review[J]. Ger Med Sci， 2011，.
3. 中华医学会消化病学分会炎症性肠病协作组. 中国炎症性肠病诊断治疗规范的共识意见[J]. 中华内科杂志， 2008， 47(1)：73-79.
4. Truelove SC， Witts LJ. Cortisone in ulcerative colitis；final reporton a therapeutic trial[J]. Br BMJ J， 1955， 2(4947)：1041-1048.
5. Cosnes J， Gower-Rousseau C， Seksik P， et al. Epidemiology and natural history of inflammatory bowel diseases[J]. Gastroenterology， 2011， 140(6)：1785-1794.
6. Fagerhol MK， Dale I， Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells[J]. Bull Eur Physiopathol Respir， 1980， 16 Suppl：273-282.
7. Rugtveit J， Brandtzaeg P， Halstensen TS， et al. Increased macrophage subset in inflammatory bowel disease：apparent recruitment from peripheral blood monocytes[J]. Gut， 1994， 35(5)：669-674.
8. Røseth AG， Aadland E， Jahnsen J， et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin， a novel granulocyte marker protein[J]. Digestion， 1997， 58(2)：176-180.
9. ：Doc03.
10. Gisbert JP， McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease[J]. Dig Liver Dis， 2009， 41(1)：56-66.
11. 沈姞，李俊霞，王化虹，等. 粪便钙卫蛋白对溃疡性结肠炎的诊断及预测复发的价值[J]. 肠外与肠内营养， 2011， 18(5)：272-276.
12. 马列婷，王亚文，乔文. 粪便钙卫蛋白对溃疡性结肠炎诊断的临床价值[J]. 西安交通大学学报：医学版， 2008， 29(3)：321-323.
13. Amati L， Passeri ME， Selicato F， et al. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease[J]. Immunopharmacol Immunotoxicol， 2006， 28(4)：665-681.
14. Costa F， Mumolo MG， Ceccarelli L， et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease[J]. Gut， 2005， 54(3)：364-368.
15. Tibble JA， Sigthorsson G， Bridger S， et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease[J]. Gastroenterology， 2000， 119(1)：15-22.
16. 张颖，王英德. 粪便钙卫蛋白、抗中性粒细胞胞浆抗体检测在溃疡性结肠炎诊断中的价值比较[J]. 中华临床医师杂志：电子版， 2012， 6(6)：1620-1622.
17. Vermeire S， Van Assche G， Rutgeerts P. Laboratory markers in IBD：useful， magic， or unnecessary toys?[J]. Gut， 2006， 55(3)：426-431.
18. Solem CA， Loftus EV Jr， Tremaine WJ， et al. Correlation ofC-reactive protein with clinical， endoscopic， histologic， and radio-graphic activity in inflammatory bowel disease[J]. Inflamm Bowel Dis， 2005， 11(8)：707-712.
19. Manz M， Burri E， Rothen C， et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort：an observational study[J]. BMC Gastroenterol， 2012， 12：5.
20. Erbayrak M， Turkay C， Eraslan E， et al. The role of fecal calprotectin in investigating inflammatory bowel diseases[J]. Clinics，.
21. Schoepfer AM， Beglinger C， Straumann A， et al. Ulcerative colitis：correlation of the rachmilewitz endoscopic activity index with fecal calprotectin， clinical activity， C-reactive protein， and blood leukocytes[J]. Inflamm Bowel Dis， 2009， 15(12)：1851-1858.
22. Lamb CA， Mohiuddin MK， Gicquel J， et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease[J]. Br J Surg， 2009， 96(6)：663-674.
23. Fagerhol MK. Calprotectin， a faecal marker of organic gastrointestinal abnormality[J]. Lancet， 2000， 356(9244)：1783-1784.
24. Mao R， Xiao YL， Gao X， et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases：a meta-analysis of pros-pective studies[J]. Inflamm Bowel Dis， 2012， 18(10)：1894-1899.
25. Schoepfer AM， Beglinger C， Straumann A， et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the lichtiger index， C-reactive protein， platelets， hemoglobin， and blood leukocytes[J]. Inflamm Bowel Dis， 2013， 19(2)：332-341.
26. 欧阳钦. 溃疡性结肠炎的治疗[J]. 中国实用内科杂志， 2010， 30(4)：383-385.
27. ， 64(5)：421-425.

Previous Article
Surgical Treatment of Stanford Type A Aortic Dissection
Next Article
右冠状动脉左心房瘘结扎术后并发脑梗死一例

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Value of Fecal Calprotectin in Activity Evaluation of Ulcerative Colitis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content